SQTL3
MCID: SMK004
MIFTS: 44

Smoking As a Quantitative Trait Locus 3 (SQTL3)

Categories: Cancer diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Smoking As a Quantitative Trait Locus 3

MalaCards integrated aliases for Smoking As a Quantitative Trait Locus 3:

Name: Smoking As a Quantitative Trait Locus 3 56 29 6
Lung Cancer Susceptibility 2 56 13 6 71
Nicotine Dependence 56 71
Nicotine Dependence, Susceptibility to 56
Sqtl3 56

Classifications:



External Ids:

OMIM 56 612052
UMLS 71 C0028043 C2677571

Summaries for Smoking As a Quantitative Trait Locus 3

MalaCards based summary : Smoking As a Quantitative Trait Locus 3, also known as lung cancer susceptibility 2, is related to tobacco addiction and substance dependence. An important gene associated with Smoking As a Quantitative Trait Locus 3 is CHRNA3 (Cholinergic Receptor Nicotinic Alpha 3 Subunit), and among its related pathways/superpathways are Transmission across Chemical Synapses and Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics. The drugs Dopamine and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and lung, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

More information from OMIM: 612052

Related Diseases for Smoking As a Quantitative Trait Locus 3

Diseases in the Smoking As a Quantitative Trait Locus 3 family:

Smoking As a Quantitative Trait Locus 1 Smoking As a Quantitative Trait Locus 2

Diseases related to Smoking As a Quantitative Trait Locus 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 tobacco addiction 32.7 CHRNA5 CHRNA3
2 substance dependence 29.9 CHRNA5 CHRNA3
3 alcohol dependence 29.8 CHRNA5 CHRNA3
4 cocaine dependence 29.5 CHRNA5 CHRNA3
5 pulmonary disease, chronic obstructive 29.3 CHRNA5 CHRNA3
6 drug dependence 10.5
7 anxiety 10.5
8 depression 10.4
9 alcohol use disorder 10.4
10 substance abuse 10.4
11 withdrawal disorder 10.4
12 mood disorder 10.4
13 attention deficit-hyperactivity disorder 10.3
14 mental depression 10.3
15 personality disorder 10.3
16 major depressive disorder 10.2
17 schizophrenia 10.2
18 major affective disorder 8 10.2
19 major affective disorder 9 10.2
20 bipolar disorder 10.2
21 conduct disorder 10.2
22 severe combined immunodeficiency 10.2
23 antisocial personality disorder 10.1
24 panic disorder 10.1
25 lung disease 10.1
26 pathological gambling 10.1
27 opiate dependence 10.1
28 disease of mental health 10.1
29 avoidant personality disorder 10.1
30 cannabis dependence 10.1
31 psychotic disorder 10.1
32 lung cancer 10.0
33 schizoaffective disorder 10.0
34 eating disorder 10.0
35 cannabis abuse 10.0
36 peripheral vascular disease 9.9
37 pain agnosia 9.9
38 social phobia 9.9
39 vascular disease 9.9
40 chronic pain 9.9
41 bladder cancer 9.9
42 pancreatic cancer 9.9
43 phobia, specific 9.9
44 smoking as a quantitative trait locus 1 9.9
45 angina pectoris 9.9
46 alexithymia 9.9
47 dysthymic disorder 9.9
48 somatization disorder 9.9
49 generalized anxiety disorder 9.9
50 atherosclerosis susceptibility 9.7

Graphical network of the top 20 diseases related to Smoking As a Quantitative Trait Locus 3:



Diseases related to Smoking As a Quantitative Trait Locus 3

Symptoms & Phenotypes for Smoking As a Quantitative Trait Locus 3

Clinical features from OMIM:

612052

GenomeRNAi Phenotypes related to Smoking As a Quantitative Trait Locus 3 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 9.17 CHRNA3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.17 CHRNA3
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.17 CHRNA3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.17 CHRNA5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.17 CHRNA3 CHRNA5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.17 CHRNA5

Drugs & Therapeutics for Smoking As a Quantitative Trait Locus 3

Drugs for Smoking As a Quantitative Trait Locus 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
3
Galantamine Approved Phase 4 357-70-0 9651
4
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
5
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
6
Citalopram Approved Phase 4 59729-33-8 2771
7
Sertraline Approved Phase 4 79617-96-2 68617
8
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
9
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
10
tannic acid Approved Phase 4 1401-55-4
11
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
12
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
13
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
14 Dopamine Agents Phase 4
15 Dopamine Uptake Inhibitors Phase 4
16 Anti-Bacterial Agents Phase 4
17 Antipsychotic Agents Phase 4
18 Tranquilizing Agents Phase 4
19 Serotonin Agents Phase 4
20 Antiparkinson Agents Phase 4
21 Dopamine Antagonists Phase 4
22 Nootropic Agents Phase 4
23 Cholinesterase Inhibitors Phase 4
24 Serotonin Uptake Inhibitors Phase 4
25 Dopamine D2 Receptor Antagonists Phase 4
26 Serotonin 5-HT1 Receptor Agonists Phase 4
27 Serotonin 5-HT2 Receptor Antagonists Phase 4
28 Dopamine agonists Phase 4
29 Liver Extracts Phase 4
30 Muscarinic Antagonists Phase 4
31 Parasympatholytics Phase 4
32 Cholinergic Antagonists Phase 4
33 Analgesics, Opioid Phase 4
34 Central Nervous System Stimulants Phase 4
35 Cytochrome P-450 Enzyme Inhibitors Phase 4
36 Autonomic Agents Phase 4
37 Antidepressive Agents Phase 4
38 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
39 Psychotropic Drugs Phase 4
40 Hypnotics and Sedatives Phase 4
41
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
42
Mineral oil Approved, Vet_approved Phase 3 8042-47-5
43
Topiramate Approved Phase 3 97240-79-4 5284627
44
Carbon monoxide Approved, Investigational Phase 2, Phase 3 630-08-0 281
45
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 3 52485-79-7 40400 644073
46
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
47
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
48
Bevacizumab Approved, Investigational Phase 3 216974-75-3
49
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
50
Propranolol Approved, Investigational Phase 3 525-66-6 4946

Interventional clinical trials:

(show top 50) (show all 532)
# Name Status NCT ID Phase Drugs
1 Treatment of Nicotine Dependence and Acute Depression Completed NCT00186446 Phase 4 bupropion and smoking cessation behavioral intervention
2 Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging Completed NCT01664741 Phase 4 Nicotine patch - transdermal;placebo
3 Effects of Intranasal Oxytocin on Cigarette Smoking Completed NCT02595749 Phase 4 Oxytocin;Placebo
4 Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study Completed NCT00596882 Phase 4
5 Varenicline for Light Smokers Completed NCT01639560 Phase 4 Varenicline;Placebo
6 Behavioral/Pharmacological Treatments for Alcohol-Nicotine Dependence Completed NCT00000447 Phase 4 naltrexone (Revia);nicotine replacement patch
7 Validation of a Novel Paradigm for Screening Medications for Nicotine Dependence Completed NCT00948649 Phase 4 Placebo;Varenicline
8 Effectiveness of Bupropion Used in Combination With the Nicotine Replacement Patch and Cognitive Behavioral Therapy for Treating Nicotine Dependent Individuals - 1 Completed NCT00142831 Phase 4 Pharmacotherapies for Smoking Cessation
9 Field Study of Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch
10 A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression Completed NCT01078298 Phase 4 varenicline;placebo
11 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
12 Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment Completed NCT00749463 Phase 4 Nicotine Gum;Nicotine Patch
13 Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy Completed NCT01980550 Phase 4 sublingual nicotine
14 Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study Completed NCT00167817 Phase 4 Aripiprazole
15 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
16 Pharmacotherapies: Efficacy, Mechanisms and Algorithms Completed NCT00332644 Phase 4 nicotine patch;nicotine lozenge;nicotine patch + nicotine lozenge;bupropion;bupropion + lozenge;placebo
17 Assessment of Smoking Topography and Behaviors During Response to Varenicline Completed NCT00948155 Phase 4 Varenicline
18 Nicotine for Marijuana Withdrawal Completed NCT01400243 Phase 4 Nicotine;Placebo Patch
19 Nicotine Replacement for Smoking Cessation During Pregnancy Completed NCT01656733 Phase 4 Nicotrol Inhaler;Placebo Inhaler
20 Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation? Completed NCT02634281 Phase 4 Varenicline;placebo
21 Neuropsychological and Psychopathological Prognosis Factors of Smoking Cessation Completed NCT01554436 Phase 4
22 A Comparison of Bupropion SR and Placebo for Smoking Cessation Completed NCT00176449 Phase 4 Bupropion SR;Placebo Oral Tablet
23 Clinical Relevance of Stress Neuroadaptation in Tobacco Dependence Completed NCT03262233 Phase 4
24 Predictors of Antidepressant Response Completed NCT02178696 Phase 4 Celexa or other antidepressant as clinically indicated
25 Smoking Cessation in a Drug Treatment Program: A Randomized Trial of Varenicline Versus Placebo. Completed NCT01286584 Phase 4 varenicline;placebo
26 Minocycline and Tobacco Craving in Smokers With Schizophrenia Completed NCT02968602 Phase 4 Minocycline
27 Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease: a Pilot Randomized Trial Completed NCT00959972 Phase 4 Varenicline;Transdermal Nicotine Patch
28 Preparing Those With Significant and Persistent Mental Illness to Quit Smoking Completed NCT01783912 Phase 4 Nicotine Patch
29 A Double-Blind, Placebo-Controlled Trial of Reward Responsivity During Nicotine Withdrawal in Smokers With Schizophrenia and Normal Controls Completed NCT00373126 Phase 4 transdermal nicotine patch
30 Impact of Carotid Plaque Screening on Smoking Cessation and Control of Other Cardiovascular Risk Factors: A Randomized Controlled Trial. Completed NCT00548665 Phase 4
31 Impact of Smoking Cessation on Sleep Completed NCT00132821 Phase 4 Bupropion;Transdermal Nicotine Patch;Placebo Bupropion;Placebo transdermal nicotine patch
32 NRT & Bupropion Mechanisms of Effectiveness in Smokers: Phase IV Trial Completed NCT01048944 Phase 4 Bupropion SR;Nicotine Patch;Placebo Patch and Placebo Pill
33 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
34 Effect of Nicotine Agonist Galantamine Added to High Potency Medications for Cognitive Function in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00320736 Phase 4 galantamine
35 Identifying Optimal, Translatable Smoking Cessation Intervention Components Completed NCT01122238 Phase 4 Nicotine Patch;Nicotine Gum;Nicotine Patch + Nicotine Gum
36 Randomized Clinical Trial Comparing a Medication, i.e., Sustained-Release Bupropion (Zyban®) With an Ultrashort (1 1/2 d) Manual-Based Psychotherapeutic Intervention, Psychodynamic Model Training® Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
37 Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers Completed NCT02245308 Phase 4 Nicotine Patches;Nicotine rescue method;Bupropion
38 The STOP Study: Real World Effectiveness of Zyban Treatment in a Clinical Population Completed NCT01015170 Phase 4 bupropion HCl
39 Treatment of Smoking Lapses and Relapses Completed NCT01807871 Phase 4 nicotine patch, experimental use;nicotine patch, labeled use
40 Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking Completed NCT00621777 Phase 4 Varenicline;Placebo
41 A Trial of the Effects of Bupropion, Nicotine Replacement Therapy and CBT on Smoking Cessation and Smoking Relapse in Patients With Schizophrenia Completed NCT00320697 Phase 4 bupropion + nicotine patch + nicotine gum or lozenges;Placebo pill + placebo patch
42 The Long-Term Quitting Study: Testing Relapse Recovery Intervention Components Completed NCT02564315 Phase 4 Nicotine Mini-Lozenge for 11 Months;Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge
43 Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation Recruiting NCT02575183 Phase 4 Varinecline (Chantix);Placebo (for Varenicline)
44 Multimodal Imaging of Progesterone/Neurosteroid Effects in Nicotine Addiction Recruiting NCT01954966 Phase 4 Progesterone;Placebo
45 Nicotine Replacement Therapy in Nicotine-dependent Arrestees: a Monocentric Randomized Simple Blind Study Recruiting NCT02905734 Phase 4 Nicotine patch
46 Efficacy and Safety of E-cigarettes for Smoking Cessation in Middle-aged Heavy Smokers Recruiting NCT03235505 Phase 4 Nicotine;Varenicline Tartrate
47 Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers Active, not recruiting NCT02378714 Phase 4 Varenicline
48 Alcohol Use and Mental Health - Pilot Test of Video-assisted Drinking Topography Active, not recruiting NCT03314454 Phase 4 Beer
49 Optimized Chronic Care for Smokers: Developing and Implementing Integrated Clinical and Systems Interventions in Primary Care - Cessation Trial Not yet recruiting NCT04188873 Phase 4 Preparation and Standard Duration Varenicline;Preparation and Extended Duration Varenicline;Standard Duration Varenicline;Extended Duration Varenicline;Preparation and Standard Duration Combination NRT;Preparation and Extended Duration Combination NRT;Standard Duration Combination NRT;Extended Duration Combination NRT
50 Varenicline for "Gradual" vs. "Abrupt" Smoking Cessation in Low-motivated COPD Smokers: A Randomized Pilot Study Not yet recruiting NCT02894957 Phase 4 Varenicline

Search NIH Clinical Center for Smoking As a Quantitative Trait Locus 3

Genetic Tests for Smoking As a Quantitative Trait Locus 3

Genetic tests related to Smoking As a Quantitative Trait Locus 3:

# Genetic test Affiliating Genes
1 Smoking As a Quantitative Trait Locus 3 29 CHRNA3 CHRNA5

Anatomical Context for Smoking As a Quantitative Trait Locus 3

MalaCards organs/tissues related to Smoking As a Quantitative Trait Locus 3:

40
Testes, Brain, Lung, Heart, Endothelial, Liver, Cortex

Publications for Smoking As a Quantitative Trait Locus 3

Articles related to Smoking As a Quantitative Trait Locus 3:

(show top 50) (show all 5079)
# Title Authors PMID Year
1
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. 61 56 6
18385739 2008
2
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. 56 6
18385676 2008
3
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. 56 6
18385738 2008
4
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. 61 56
20418888 2010
5
Association of serum cotinine level with a cluster of three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15. 61 56
19628476 2009
6
Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. 61 6
19443489 2009
7
Novel genes identified in a high-density genome wide association study for nicotine dependence. 61 56
17158188 2007
8
Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. 61 56
17135278 2007
9
A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction. 6
20643934 2010
10
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. 56
20418889 2010
11
Genome-wide meta-analyses identify multiple loci associated with smoking behavior. 56
20418890 2010
12
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. 56
18978787 2008
13
Dissociating wanting and anticipated liking from consummatory liking in smokers with different levels of nicotine dependence. 61
31838369 2020
14
Menthol Cigarettes and Smoking Cessation among Adult Smokers in the US. 61
32019657 2020
15
Altered subcallosal and posterior cingulate cortex-based functional connectivity during smoking cue and mental simulation processing in smokers. 61
31647945 2020
16
The Interplay Between Tobacco Dependence and Sleep Quality Among Young Adults. 61
30463440 2020
17
The time-varying effect of alcohol use on cigarette smoking relapse risk. 61
31726424 2020
18
Looming Vulnerability and Smoking Cessation Attempts. 61
32034908 2020
19
Weak smoking cessation awareness in primary health care before surgery: a real-world, retrospective cohort study. 61
32019399 2020
20
Relationship Between Nicotine Intake and Reward Function in Rats With Intermittent Short Versus Long Access to Nicotine. 61
30958557 2020
21
Associations of Adverse Childhood Experiences to Smoking and Nicotine Dependence Among Adolescent Psychiatric Inpatients. 61
31564010 2020
22
Sibling comparisons elucidate the associations between educational attainment polygenic scores and alcohol, nicotine and cannabis. 61
31659820 2020
23
Menthol cigarette smoking is associated with greater subjective reward, satisfaction, and "throat hit", but not greater behavioral economic demand. 61
31648140 2020
24
Psychiatric comorbidities in a comparative effectiveness smoking cessation trial: Relations with cessation success, treatment response, and relapse risk factors. 61
31864163 2020
25
Resting-State Connectivity in Former, Current, and Never Smokers. 61
30590742 2020
26
Goal-Directed and Habitual Control in Smokers. 61
30768206 2020
27
Delivery and implementation of an algorithm for smoking cessation treatment for people living with HIV and AIDS. 61
31174425 2020
28
Verbal suggestions of nicotine content modulate ventral tegmental neural activity during the presentation of a nicotine-free odor in cigarette smokers. 61
31812330 2020
29
Capturing habitualness of drinking and smoking behavior in humans. 61
31816490 2020
30
The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice. 61
31628204 2020
31
[Policy recommendation for the regulation of heated tobacco products based on evidence review of their health effects and influence on tobacco control]. 61
32023592 2020
32
Comparison of Allen Carr's Easyway programme with a specialist behavioural and pharmacological smoking cessation support service: a randomized controlled trial. 61
31968400 2020
33
Use of Potentially Reduced Exposure Tobacco Products Among American Indian Smokeless Tobacco Users: Associations With Cessation Behaviors and Cotinine Levels. 61
31835016 2020
34
Fagerström Test and Heaviness Smoking Index. Are they Interchangeable as a Dependence Test for Nicotine? 61
31519135 2020
35
Craving and Cue Reactivity in Nicotine-Dependent Tobacco Smokers Is Associated With Different Insula Networks. 61
31706906 2020
36
Effort-based decision making varies by smoking status. 61
31900525 2020
37
Characteristics, outcome and factors associated with success of quitting smoking in 77 people living with HIV/AIDS who received smoking cessation therapy in Japan. 61
31161725 2020
38
The association between cognitive coping strategies and treatment outcomes in smokers with PTSD. 61
31120265 2020
39
Sexual minority substance use disparities: Bisexual women at elevated risk relative to other sexual minority groups. 61
31810051 2020
40
A multi-locus predictiveness curve and its summary assessment for genetic risk prediction. 61
30612522 2020
41
Evaluating the Changes of White Matter Microstructures in Tobacco Addicts Based on Diffusion Tensor Imaging. 61
31899914 2020
42
PhenX: Host: Biobehavioral measures for tobacco regulatory research. 61
31992659 2020
43
Time to First Cigarette: A Potential Clinical Screening Tool for Nicotine Dependence. 61
31972768 2020
44
Cigarette smoking and nicotine dependence trajectories among incident adolescent smokers. 61
31970408 2020
45
Age of tobacco use initiation and association with current use and nicotine dependence among US middle and high school students, 2014-2016. 61
30498008 2020
46
Neural circuits and nicotinic acetylcholine receptors mediate the cholinergic regulation of midbrain dopaminergic neurons and nicotine dependence. 61
31554960 2020
47
Demonstration of critical role of GRIN3A in nicotine dependence through both genetic association and molecular functional studies. 61
30741440 2020
48
Corrigendum to "Assessing nicotine dependence in adolescent E-cigarette users: The 4-item Patient-Reported Outcomes Measurement Information System (PROMIS) Nicotine Dependence Item Bank for electronic cigarettes" [Drug Alcohol Depend. 188 (2018) 60-63]. 61
31640884 2020
49
Onset of Regular Smoking Before Age 21 and Subsequent Nicotine Dependence and Cessation Behavior Among US Adult Smokers. 61
31944932 2020
50
Nicotine dependence (trait) and acute nicotinic stimulation (state) modulate attention but not inhibitory control: converging fMRI evidence from Go-Nogo and Flanker tasks. 61
31995811 2020

Variations for Smoking As a Quantitative Trait Locus 3

ClinVar genetic disease variations for Smoking As a Quantitative Trait Locus 3:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CHRNA5 NM_000745.3(CHRNA5):c.1192G>A (p.Asp398Asn)SNV drug response 17497 rs16969968 15:78882925-78882925 15:78590583-78590583
2 CHRNA3 NM_000743.5(CHRNA3):c.645C>T (p.Tyr215=)SNV drug response 17503 rs1051730 15:78894339-78894339 15:78601997-78601997

Expression for Smoking As a Quantitative Trait Locus 3

Search GEO for disease gene expression data for Smoking As a Quantitative Trait Locus 3.

Pathways for Smoking As a Quantitative Trait Locus 3

GO Terms for Smoking As a Quantitative Trait Locus 3

Cellular components related to Smoking As a Quantitative Trait Locus 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.26 CHRNA5 CHRNA3
2 neuron projection GO:0043005 9.16 CHRNA5 CHRNA3
3 postsynaptic membrane GO:0045211 8.96 CHRNA5 CHRNA3
4 acetylcholine-gated channel complex GO:0005892 8.62 CHRNA5 CHRNA3

Biological processes related to Smoking As a Quantitative Trait Locus 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.48 CHRNA5 CHRNA3
2 ion transmembrane transport GO:0034220 9.46 CHRNA5 CHRNA3
3 chemical synaptic transmission GO:0007268 9.43 CHRNA5 CHRNA3
4 regulation of membrane potential GO:0042391 9.4 CHRNA5 CHRNA3
5 excitatory postsynaptic potential GO:0060079 9.37 CHRNA5 CHRNA3
6 nervous system process GO:0050877 9.32 CHRNA5 CHRNA3
7 response to nicotine GO:0035094 9.26 CHRNA5 CHRNA3
8 neuromuscular synaptic transmission GO:0007274 9.16 CHRNA5 CHRNA3
9 synaptic transmission, cholinergic GO:0007271 8.96 CHRNA5 CHRNA3
10 behavioral response to nicotine GO:0035095 8.62 CHRNA5 CHRNA3

Molecular functions related to Smoking As a Quantitative Trait Locus 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.37 CHRNA5 CHRNA3
2 extracellular ligand-gated ion channel activity GO:0005230 9.32 CHRNA5 CHRNA3
3 ligand-gated ion channel activity GO:0015276 9.26 CHRNA5 CHRNA3
4 acetylcholine binding GO:0042166 9.16 CHRNA5 CHRNA3
5 acetylcholine-gated cation-selective channel activity GO:0022848 8.96 CHRNA5 CHRNA3
6 acetylcholine receptor activity GO:0015464 8.62 CHRNA5 CHRNA3

Sources for Smoking As a Quantitative Trait Locus 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....